PolyU’s new Advanced Therapy Product Laboratory gives hope to spinal cord injury patients, supporting Hong Kong’s development into an international health and medical innovation hub

The Hong Kong Polytechnic University (PolyU) strives to promote educational and research development in the fields of medicine and health. Leveraging its state-of-the-art facilities and strengths in interdisciplinary research, the University is committed to supporting Hong Kong’s development into an international health and medical innovation hub by advancing precision medicine and personalised treatment.

PolyU will actively promote precision and personalised medicine through the introduction of advanced therapy products (ATPs). This initiative will promote medical innovation and interdisciplinary collaboration, accelerating the development of the local ATPs ecosystem while enhancing Hong Kong’s global competitiveness in biopharmaceuticals. The University is now planning to manufacture cell therapy products for spinal cord injuries, which will be further complemented by the post-surgery rehabilitation programme and utilise the expertise of PolyU Department of Rehabilitation Sciences (RS), offering a one-stop approach from precision medicine to rehabilitation to bring new hope to hemiplegia and paralysis patients.

The newly established PolyU Advanced Therapy Product (ATP) Laboratory is a Pharmaceutical Inspection Co-operation Scheme’s Good Manufacturing Practice (PIC/S GMP)-compliant facility, focusing on clinical research in immunotherapy, cell therapy, gene therapy and regenerative medicine. Led by Prof. Larry CHOW Ming-cheung, Head of the Department of Applied Biology and Chemical Technology, the team has made plans to collaborate with the biopharmaceutical industry and will commence clinical trials once the Laboratory is granted the Licence for Manufacturer and the Certificate for Clinical Trial and Medicinal Test by the HKSAR Government’s Department of Health.

Medical needs of spinal cord injury patients

The spinal cord is an essential part of the central nervous system. Any damage to it may affect the function of the spinal nerves at and below the injury site. According to the World Health Organization, more than 15 million people are living with spinal cord injuries globally. Common symptoms include tetraplegia, paraplegia, loss of sensation, impaired bladder and bowel control, chronic pain, and movement disorders, which seriously affect patients’ physical and mental health.

Currently, there is no effective cure for spinal cord injuries. The medical sector has, in recent years, endeavoured to develop technology for precision medicine, including stem cell therapy, gene therapy, biomaterials and tissue engineering, and electrical stimulation therapy, to help repair the injured spinal nerves. Previous research has indicated that, nevertheless, advanced therapy alone is not effective enough for patients to fully regain their mobility. It has to be combined with cross-professional rehabilitation training to enhance the treatment outcomes.

PolyU ATP Laboratory: A pioneer in precision medicine

The Laboratory has been established with the grants provided by the University Grants Committee (UGC) and PolyU. Equipped with a Production Site, Quality Control Laboratory and Training Laboratory, it will serve as a robust platform for the development and clinical application of local ATPs. The ATP team, in collaboration with scientific research enterprises, the biopharmaceutical industry, and academic institutions, will focus on clinical trials for spinal cord injury patients during its first phase of work. It will make use of human leukocyte antigen (HLA)-matched umbilical cord blood received from the industry partner to produce umbilical cord blood-derived mononuclear cells. Quality control and product packaging procedures will also be performed. PIC/S GMP-compliant final products will then be sent to the hospitals for transplantation in patients.

The project will also foster collaboration on neurological disorders research at PolyU, further unleashing the University’s interdisciplinary strengths across neuroscience, molecular biology, immunology, biological engineering, rehabilitation sciences, and more.

Interdisciplinary integration enables patient-centred care

PolyU is the only local university that offers a one-stop solution from treatment to rehabilitation. It has been nurturing numerous allied health professionals such as physical therapists and occupational therapists who work with medical teams to provide extended care through rehabilitation and the application of technology-assisted diagnosis.

With the ATP Laboratory concentrating on advanced therapy and RS providing physiotherapy and other relevant allied health services, patients will be able to receive comprehensive care. During spinal cord injury treatment, for instance, the injured tissue of the patients can be repaired by stem cell transplantation, and their muscle strength and mobility can be retrained through a rehabilitation programme.

Prof. Larry Chow said, “There is significant potential for growth in the production of advanced therapy products in Hong Kong nowadays. The ATP Laboratory at PolyU aligns with the international good manufacturing practices, and will contribute to nurturing more biopharmaceutical talents in the region. Through collaboration with industry partners, we aim to achieve breakthroughs in cell therapy and immunotherapy, translating the research outcomes of the University by facilitating cutting-edge medical research and clinical trials, thereby advancing Hong Kong’s medical technology development.”

PolyU has submitted a proposal to the HKSAR Government for the establishment of the third medical school in Hong Kong. Capitalising on its research strengths in health technologies, engineering and artificial intelligence, as well as its experience in training allied health professionals over the past half-century, the University is confident in its ability to nurture interdisciplinary medical leaders and foster the development of Hong Kong into an international health and medical innovation hub.

***END***